Acetylation of proteins as novel target for antitumor therapy: Review article

Amino Acids

Volumn 26, Issue 4, 2004, Pages 435-441

  Di Gennaro, E ^a,b   Bruzzese, F ^a   Caraglia, M ^b   Abruzzese, A ^b   Budillon, A ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Cancer; Chromatin; Histone; Histone deacetylase; Histone deacetylase inhibitors; Transglutaminase

Indexed keywords

4 N ACETYLDINALINE; ALPHA TUBULIN; BENZAMIDE; BUTYRIC ACID; CHAPERONE; DEPSIPEPTIDE; ERYTHROID KRUPPEL LIKE FACTOR; FR 901228; HEAT SHOCK PROTEIN 90; HISTONE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KARYOPHERIN ALPHA; LQ 824; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; NUCLEAR FACTOR Y; PROTEIN C JUN; PROTEIN P53; PROTEIN P73; PYROXAMIDE; T CELL FACTOR PROTEIN; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E2F; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR HMGI; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; VALPROIC ACID;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMATIN CONDENSATION; CHROMATIN STRUCTURE; CONFERENCE PAPER; CYTOSKELETON; ENZYME ACTIVITY; ENZYME ANALYSIS; GENETIC TRANSCRIPTION; HUMAN; NUCLEAR IMPORT; PRIORITY JOURNAL; TRANSCRIPTION REGULATION;

EID: 4143128717     PISSN: 09394451     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00726-004-0087-3     Document Type: Conference Paper

References (55)

1. Allfrey VG, Littau VC, Mirsky AE (1963) On the role of histones in regulation ribonucleic acid synthesis in the cell nucleus. Proc Natl Acad Sci USA 49: 414-421
2. Ashcroft M, Vousden KH (1999) Regulation of p53 stability. Oncogene 18: 7637-7543
3. Boyes J, Byfield P, Nakatani Y, Ogryzko V (1998) Regulation of activity of the transcription factor GATA-1 by acetylation. Nature 396: 594-598
4. Cheung P, Allis CD, Sassone-Corsi P (2000) Signaling to chromatin through histone modifications. Cell 103: 263-271
5. Cress WD, Seto E (2000) Histone deacetylases, transcriptional control, and cancer. J Cell Physiol 184: 1-16
6. Deckert J, Struhl K (2001) Histone acetylation at promoters is differentially affected by specific activators and repressors. Mol Cell Biol 21: 2726-2735
7. Deroanne CF, Bonjean K, Servotte S, Devy L, Colige A, Clausse N, Blacher S, Verdin E, Foidart JM, Nusgens BV, Castronovo V (2002) Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 21: 427-436
8. Dhordain P, Lin RJ, Quief S, Lantoine D, Kerckaert JP, Evans RM, Albagli O (1998) The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression. Nucleic Acids Res 26: 4645-4651
9. Felsenfeld G, Groudine M (2003) Controlling the double helix. Nature 421: 448-453
10. Fesus L, Piacentini M (2002) Transglutaminase 2: an enigmatic enzyme with diverse functions. Trends Biochem Sci 27: 534-539
11. Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, Breslow R, Pavletich NP (1999) Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401: 188-193
12. Fischer DD, Cai R, Bhatia U, Asselbergs FA, Song C, Terry R, Trogani N, Widmer R, Atadja P, Cohen D (2002) Isolation and characterization of a novel class II histone deacetylase, HDAC10. J Biol Chem 277: 6656-6666
13. Fischle W, Wang Y, Allis CD (2003) Binary switches and modification cassettes in histone biology and beyond. Nature 425: 475-479
14. Fuino L, Bali P, Wittmann S, Donapaty S, Guo F, Yamaguchi H, Wang HG, Atadja P, Bhalla K (2003) Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol Cancer Ther 2: 971-984
15. Gao L, Cueto MA, Asselbergs F, Atadja P (2002) Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J Biol Chem 277: 25748-25755
16. Gayther SA, Batley SJ, Linger L, Bannister A, Thorpe K, Chin SF, Daigo Y, Russell P, Wilson A, Sowter HM, Delhanty JD, Ponder BA, Kouzarides T, Caldas C (2000) Mutations truncating the EP300 acetylase in human cancers. Nat Genet 24: 300-303
17. Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, Davidsen SK (2003) Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2: 151-163
18. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG, Heinzel T (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20: 6969-6978
19. Grant PA, Berger SL (1999) Histone acetyltransferase complexes. Semin Cell Dev Biol 10: 169-177
20. Gray SG, Ekstrom TJ (2001) The human histone deacetylase family. Exp Cell Res 262: 75-83
21. Gregory PD, Wagner K, Horz W (2001) Histone acetylation and chromatin remodeling. Exp Cell Res 265: 195-202
22. Gu W, Roeder RG (1997) Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90: 595-606
23. Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL (2003) Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci USA 100: 4389-4394
24. He LZ, Tolentino T, Grayson P, Zhong S, Warrell RP Jr, Rifkind RA, Marks PA, Richon VM, Pandolfi PP (2001) Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest 108: 1321-1330
25. Hoshikawa Y, Kwon HJ, Yoshida M, Horinouchi S, Beppu T (1994) Trichostatin A induces morphological changes and gelsolin expression by inhibiting histone deacetylase in human carcinoma cell lines. Exp Cell Res 214: 189-197
26. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, Yoshida M, Wang XF, Yao TP (2002) HDAC6 is a microtubule-associated deacetylase. Nature 417: 455-458
27. Jin S, Scotto KW (1998) Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y. Mol Cell Biol 18: 4377-4384
28. Johnstone RW, Licht JD (2003) Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 4: 13-18
29. Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428
30. th EORTC-NCI-AACR Symposium, Frankfurt, Germany, 19-22 November 2002)
31. Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F (2003) Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 63: 7291-7300
32. Kim YB, Lee KH, Sugita K, Yoshida M, Horinouchi S (1999) Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene 18: 2461-2470
33. Lin RJ, Nagy L, Inoue S, Shao W, Miller WH Jr, Evans RM (1998) Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 391: 811-814
34. Liu LT, Chang HC, Chiang LC, Hung WC (2003) Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. Cancer Res 63: 3069-3072
35. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK (2001) Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1: 194-202
36. Martinez-Balbas MA, Bauer UM, Nielsen SJ, Brehm A, Kouzarides T (2000) Regulation of E2F1 activity by acetylation. EMBO J 19: 662-671
37. Munshi N, Merika M, Yie J, Senger K, Chen G, Thanos D (1998) Acetylation of HMG I(Y) by CBP turns off IFN beta expression by disrupting the enhanceosome. Mol Cell 2: 457-467
38. Nakamura M, Saito H, Ebinuma H, Wakabayashi K, Saito Y, Takagi T, Nakamoto N, Ishii H (2001) Reduction of telomerase activity in human liver cancer cells by a histone deacetylase inhibitor. J Cell Physiol 187: 392-401
39. Nimmanapalli R, Bali P, O'Bryan E, Fuino L, Guo F, Wu J, Houghton P, Bhalla K (2003) Arsenic Trioxide Inhibits Translation of mRNA of bcr-abl, Resulting in Attenuation of Bcr-Abl Levels and Apoptosis of Human Leukemia Cells. Cancer Res 63: 7950-7958
40. Pandolfi PP (2001) In vivo analysis of the molecular genetics of acute promyelocytic leukemia. Oncogene 20: 5726-5735
41. Peart MJ, Tainton KM, Ruefli AA, Dear AE, Sedelies KA, O'Reilly LA, Waterhouse NJ, Trapani JA, Johnston RW (2003) Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res 63: 4460-4471
42. Piekarz RL, Robey R, Sandor V, Bakke S, Wilson WH, Dahmoush L, Kingma DM, Turner ML, Altemus R, Bates SE (2001) Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 98: 2865-2868
43. Plumb JA, Finn PW, Williams RJ, Bandara MJ, Romero MR, Watkins CJ, La Thangue NB, Brown R (2003) Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2: 721-728
44. Richmond TJ, Finch JT, Rushton B, Rhodes D, Klug A (1984) Structure of the nucleosome core particle at 7 A resolution. Nature 311: 532-537
45. Rosato RR, Almenara JA, Grant S (2003) The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res 63: 3637-3645
46. Ruefli AA, Ausserlechner MJ, Bernhard D, Sutton VR, Tainton KM, Kofler R, Smyth MJ, Johnstone RW (2001) The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA 98: 10833-10838
47. Sambucetti LC, Fischer DD, Zabludoff S, Kwon PO, Chamberlin H, Trogani N, Xu H, Cohen D (1999) Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J Biol Chem 274: 34940-34947
48. Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, Brooks R, Piekarz RL, Tucker E, Figg WD, Chan KK, Goldspiel B, Fojo AT, Balcerzak SP, Bates SE (2002) Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 8: 718-728
49. Sato N, Ohtake Y, Kato H, Abe S, Kohno H, Ohkubo Y (2003) Effects of polyamines on histone polymerization. J Protein Chem 22: 303-307
50. Van Lint C, Emiliani S, Verdin E (1996) The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr 5: 245-253
51. Wolffe AP, Hayes JJ (1999) Chromatin disruption and modification. Nucleic Acids Res 27: 711-720
52. Yamashita K, Upadhyay S, Osada M, Hoque MO, Xiao Y, Mori M, Sato F, Meltzer SJ, Sidransky D (2002) Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2: 485-495
53. Yu X, Guo ZS, Marcu, MG, Neckers L, Nguyen DM, Chen GA, Schrump DS (2002) Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst 94: 504-513
54. Zhong S, Goto H, Inagaki M, Dong Z (2003) Phosphorylation at serine 28 and acetylation at lysine 9 of histone H3 induced by trichostatin A. Oncogene 22: 5291-5297
55. Zhou X, Marks PA, Rifkind RA, Richon VM (2001) Cloning and characterization of a histone deacetylase, HDAC9. Proc Natl Acad Sci USA 98: 10572-10577